International research has confirmed that Human Metapneumovirus (HMPV) can, in rare cases, affect the central nervous system, potentially triggering seizures, encephalitis, and other neurological complications—symptoms that go beyond the respiratory illness doctors traditionally associate with the pathogen.
Why This Matters:
• Neurological complications like seizures and brain inflammation have been documented in some HMPV cases, particularly among children, elderly patients, and immunocompromised individuals, though these complications remain relatively rare.
• Global HMPV hospitalizations have increased, with detection rates rising internationally in early 2025, and medical professionals are urging awareness of these potential neurological manifestations.
• No approved vaccine or specific treatment exists yet, making early symptom recognition important for potentially life-saving medical intervention.
• Thailand's winter and spring respiratory season typically sees HMPV outbreaks, making awareness of the full symptom profile relevant for residents.
From Respiratory Virus to Recognized Brain Complications
For years, HMPV circulated as a common cold-like virus, causing coughs, fevers, and congestion mostly in young children and older adults. Growing research has highlighted that, in rare cases, the virus can affect the central nervous system. Direct viral invasion of brain tissue has been documented in rare cases through cerebrospinal fluid (CSF) analysis, where HMPV RNA was detected. Research also suggests that the virus can compromise the blood-brain barrier, the protective membrane that normally shields the central nervous system from pathogens and inflammatory agents.
The mechanisms behind HMPV's potential neurological effects appear multifaceted. In some patients, the virus may invade brain tissue directly. In others, neuroinflammation—the release of inflammatory cytokines such as IL-6, IL-8, CCL2, and CCL4—can trigger symptoms without the virus physically entering the brain. A third pathway involves immune-mediated damage, where the body's own defense system may overreact and attack healthy neural tissue, a phenomenon clinicians sometimes manage with corticosteroids or intravenous immunoglobulins to reduce the inflammatory response.
What Neurological Symptoms Look Like
Residents and parents in Thailand should be alert to warning signs that may indicate neurological involvement with HMPV. The most frequently reported neurological manifestation is seizures, including both fever-related (febrile) and non-fever-related (afebrile) episodes. Research indicates HMPV cases can produce seizures, and these have been reported at rates comparable to or potentially higher than infections caused by respiratory syncytial virus (RSV), a related pathogen.
Beyond seizures, HMPV can potentially cause encephalitis—inflammation of brain tissue marked by altered mental status, confusion, personality changes, severe headaches, and focal neurological deficits like limb weakness or speech difficulty. In severe cases, patients may experience status epilepticus, a medical emergency characterized by prolonged or repeated seizures without full recovery of consciousness between episodes.
Importantly, neurological symptoms can appear with or without significant respiratory involvement. A child might present with minimal coughing or fever but develop sudden confusion or a seizure, which can complicate diagnosis. CSF analysis in these cases often shows normal or only mildly elevated protein levels with minimal white blood cell infiltration, potentially leading clinicians to initially overlook HMPV. MRI scans may reveal cortical and subcortical T2/FLAIR hyperintensities, patterns associated with brain inflammation.
The Scale of Risk in 2025-2026
While exact case counts of HMPV neurological complications remain limited—partly because these complications are rare and potentially underrecognized due to limited awareness and testing—the overall rise in HMPV infections provides context. In the United States, HMPV detection rates increased from 0.42% in late September 2025 to 5.37% by early March 2026. Other regions including China, India, and Europe have also documented increases in HMPV detection during late 2024 and 2025.
For Thailand, international patterns typically signal seasonal spikes in respiratory viruses. HMPV infections peak during winter and spring months, when cooler weather favors respiratory virus circulation. Medical professionals are urging heightened awareness of HMPV during these seasonal periods to ensure appropriate diagnosis and care.
What This Means for Residents
The absence of a vaccine or targeted antiviral drug makes prevention and early recognition essential. Frequent handwashing, avoiding face-touching, cleaning high-contact surfaces, covering coughs and sneezes, and maintaining distance from visibly ill individuals remain the most effective preventive measures. Parents with young children, families caring for elderly relatives, and individuals with compromised immune systems—including transplant recipients or those undergoing chemotherapy—should be especially attentive to symptoms.
When neurological symptoms appear, medical evaluation is important. Thai hospitals equipped with molecular diagnostic testing can detect HMPV through PCR analysis of respiratory samples and, when indicated, cerebrospinal fluid testing. Treatment remains largely supportive: hydration, rest, fever management, and in severe cases, oxygen therapy or mechanical ventilation. For encephalitis presentations, healthcare providers may administer immunomodulatory therapies to reduce brain inflammation, though these are general supportive interventions rather than HMPV-specific protocols.
The Research Pipeline
International scientists are working to develop treatments and preventive measures. Several monoclonal antibodies targeting the HMPV fusion protein have shown neutralizing activity in laboratory and animal models, similar to successful therapies developed for RSV. However, none have yet entered clinical trials. Vaccine candidates are being developed across multiple platforms—subunit vaccines based on the fusion protein, live attenuated formulations, vector-based designs, and mRNA technology—with some early-phase trials showing promise in adult populations.
For treatment, researchers are exploring existing antivirals. Ribavirin, approved for RSV, has demonstrated activity against HMPV in laboratory studies and has been used in some severe human cases, particularly among immunocompromised patients. Computational research has identified other FDA-approved drugs like remdesivir and peramivir as potential candidates based on laboratory analysis. Scientists are also developing laboratory models using human neurons and brain tissue to better understand how the virus may affect the nervous system.
Preliminary animal studies have suggested that HMPV infection could potentially cause lasting changes in behavior and cognitive function weeks after acute illness resolves, raising questions about long-term effects. However, it remains unknown whether these preliminary findings would apply to humans, and much more research is needed.
Practical Takeaways
For Thailand residents, awareness of HMPV's potential neurological effects is valuable during respiratory illness season. If a family member develops respiratory symptoms followed by seizures, confusion, or unusual behavioral changes, request HMPV testing as part of standard respiratory evaluation. Healthcare providers should consider HMPV in the differential diagnosis of unexplained encephalitis or seizures during outbreak periods.
While neurological complications from HMPV remain relatively rare, the growing recognition of these potential effects, combined with the virus's seasonal circulation in Thailand and the current lack of specific treatments, makes awareness and prompt medical attention important. Practicing good hygiene, recognizing potential neurological warning signs, and seeking timely medical evaluation remain the most reliable safeguards for residents during respiratory season.
As research into vaccines and antivirals continues to advance, prevention of the initial respiratory infection may ultimately prevent neurological complications entirely. Until effective preventive measures become available, maintaining awareness and following basic precautions represent prudent steps for Thailand's residents.
